Drugs / Epinephrin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial · 1 missed | ||||||
| Phase 4 | NCT05867342 | May 2017 → Aug 2018 | esophageal varices with bleeding | Stanford University | Completed | Missed primary |
| Phase not applicable2 trials | ||||||
| — | NCT05095259 | Dec 2019 → Dec 2023 | type 1 diabetes mellitus | Nordsjaellands Hospital | Unknown | No outcome recorded |
| — | NCT01075581 | Apr 2010 → Apr 2011 | cardiac rhythm disease, essential hypertension, hypotensive disorder | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT02691442 Comparator | Dec 2010 → Dec 2015 | peripheral nervous system disorder | University Hospital, Antwerp | Completed | No outcome recorded |
| — | NCT05624957 Comparator | Nov 2022 → May 2023 | — | Minia University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Epinephrin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05867342 ↗ |
| Known as | Epinephrine | “Epinephrine are prepared in 100 ml isotone saline solution according to weight and infused in 3 different infusion rates: 10 ng∙kg-1∙min-1, 25 ng∙kg-1∙min-1 and 50...” NCT05095259 ↗ |
| Route | Intranasal | “intranasal injection of epinephrine” NCT01075581 ↗ |